Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vaxcyte, Inc.
Report date December 30, 2022 · Filed January 04, 2023
Section 16 reporting ended · disclosed 2023-01-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.95 · Expires 2032-12-30 | Direct | 15,000 |
Reported balance
After 2022-12-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-30 · Grant · Acquired 15,000 · Balance 15,000 F1: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 30, 2022 Filed Jan 4, 2023 16:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $47.95 | $0.00 |
DisclosureSEC source: 0001209191-23-000964 · doc4.xml · derivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-12-30 F1 · derivative.exercise_date: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 16:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 865 | $26.38 | $22,818.70 |
DisclosureSEC source: 0001209191-22-049023 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,822 F1 · kind: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 16:47 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,000 | $25.93 | $77,784.90 |
DisclosureSEC source: 0001209191-22-047354 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,687 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.685 to $26.09. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 17:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,000 | $25.00 | $75,000.00 |
DisclosureSEC source: 0001209191-22-043547 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,687 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 17:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,000 | $25.00 | $75,000.00 |
DisclosureSEC source: 0001209191-22-043024 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,687 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 23, 2022 Filed May 25, 2022 16:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,000 | $26.22 | $78,670.50 |
DisclosureSEC source: 0001209191-22-031865 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,687 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.72 to $26.61. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 1,562 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 17, 2022. Read SEC document |
| April 22, 2022 Filed Apr 26, 2022 17:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,000 | $25.00 | $75,000.00 |
DisclosureSEC source: 0001209191-22-025654 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,125 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 18:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,000 | $25.00 | $75,000.00 |
DisclosureSEC source: 0001209191-22-020962 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 17:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 6,000 | $25.00 | $150,000.00 |
DisclosureSEC source: 0001209191-22-018522 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,125 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 20:53 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001209191-22-016522 · doc4.xml · derivative · entry 2 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-03-01 F2 · derivative.exercise_date: 1/48 of shares subject to the option vest on April 2, 2022, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 20:53 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016522 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,125 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2022 and 12.5% of the shares every six months thereafter. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 16:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 6,000 | $25.00 | $150,000.00 |
DisclosureSEC source: 0001209191-21-071604 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,125 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 17:55 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,000 | $25.00 | $75,000.00 |
DisclosureSEC source: 0001209191-21-062762 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,125 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 17:04 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,307 | $25.20 | $133,724.19 |
DisclosureSEC source: 0001209191-21-057651 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,125 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.00 to $25.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 1,841 shares acquired under the Employee Stock Purchase Plan on May 17, 2021. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | OtherStock Option (right to buy) · Derivative | 7,611 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-21-025999 · doc4.xml · derivative · entry 5 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,027 Underlying: Common Stock · 7,611 shares Expires 2029-03-20 F1 · kind: Transfer of shares and the reporting person's economic interest in stock options (right to buy) to reporting person's spouse pursuant to a property settlement agreement in connection with separation proceedings. While the reporting person will retain the options, the reporting person's spouse will receive the economic benefit from, and has sole discretion with respect to, the portion of the options representing the spouse's transferred economic interest, including exercises thereof and sales of shares underlying such portion. Accordingly, the reporting person will not report beneficial ownership of or dispositions of the portion of such options representing the spouse's transferred economic interest, nor will the reporting person report beneficial ownership of or acquisitions or dispositions of the underlying shares, in future Section 16(a) filings. F4 · derivative.exercise_date: As of the date of transfer, the shares subject to the option representing the reporting person's remaining economic interest will vest in monthly installments with respect to 617 shares from May 1, 2021 to January 1, 2023. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | OtherStock Option (right to buy) · Derivative | 21,871 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-21-025999 · doc4.xml · derivative · entry 4 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,197 Underlying: Common Stock · 21,871 shares Expires 2028-07-23 F1 · kind: Transfer of shares and the reporting person's economic interest in stock options (right to buy) to reporting person's spouse pursuant to a property settlement agreement in connection with separation proceedings. While the reporting person will retain the options, the reporting person's spouse will receive the economic benefit from, and has sole discretion with respect to, the portion of the options representing the spouse's transferred economic interest, including exercises thereof and sales of shares underlying such portion. Accordingly, the reporting person will not report beneficial ownership of or dispositions of the portion of such options representing the spouse's transferred economic interest, nor will the reporting person report beneficial ownership of or acquisitions or dispositions of the underlying shares, in future Section 16(a) filings. F3 · derivative.exercise_date: As of the date of transfer, the shares subject to the option representing the reporting person's remaining economic interest will vest in monthly installments with respect to 1,459 shares from April 24, 2021 to July 24, 2022. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | OtherStock Option (right to buy) · Derivative | 14,253 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-025999 · doc4.xml · derivative · entry 3 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,173 Underlying: Common Stock · 14,253 shares Expires 2027-05-17 F1 · kind: Transfer of shares and the reporting person's economic interest in stock options (right to buy) to reporting person's spouse pursuant to a property settlement agreement in connection with separation proceedings. While the reporting person will retain the options, the reporting person's spouse will receive the economic benefit from, and has sole discretion with respect to, the portion of the options representing the spouse's transferred economic interest, including exercises thereof and sales of shares underlying such portion. Accordingly, the reporting person will not report beneficial ownership of or dispositions of the portion of such options representing the spouse's transferred economic interest, nor will the reporting person report beneficial ownership of or acquisitions or dispositions of the underlying shares, in future Section 16(a) filings. F2 · derivative.exercise_date: The shares subject to the option representing the reporting person's remaining economic interest are fully vested and exercisable. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | OtherStock Option (right to buy) · Derivative | 4,168 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-21-025999 · doc4.xml · derivative · entry 2 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,168 Underlying: Common Stock · 4,168 shares Expires 2026-04-19 F1 · kind: Transfer of shares and the reporting person's economic interest in stock options (right to buy) to reporting person's spouse pursuant to a property settlement agreement in connection with separation proceedings. While the reporting person will retain the options, the reporting person's spouse will receive the economic benefit from, and has sole discretion with respect to, the portion of the options representing the spouse's transferred economic interest, including exercises thereof and sales of shares underlying such portion. Accordingly, the reporting person will not report beneficial ownership of or dispositions of the portion of such options representing the spouse's transferred economic interest, nor will the reporting person report beneficial ownership of or acquisitions or dispositions of the underlying shares, in future Section 16(a) filings. F2 · derivative.exercise_date: The shares subject to the option representing the reporting person's remaining economic interest are fully vested and exercisable. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | OtherCommon Stock | 38,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-025999 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,591 F1 · kind: Transfer of shares and the reporting person's economic interest in stock options (right to buy) to reporting person's spouse pursuant to a property settlement agreement in connection with separation proceedings. While the reporting person will retain the options, the reporting person's spouse will receive the economic benefit from, and has sole discretion with respect to, the portion of the options representing the spouse's transferred economic interest, including exercises thereof and sales of shares underlying such portion. Accordingly, the reporting person will not report beneficial ownership of or dispositions of the portion of such options representing the spouse's transferred economic interest, nor will the reporting person report beneficial ownership of or acquisitions or dispositions of the underlying shares, in future Section 16(a) filings. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 20:06 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001209191-21-025761 · doc4.xml · derivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-31 F1 · derivative.exercise_date: 1/48 of shares subject to the option vest on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-020468 · doc4.xml · derivative · entry 3 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,426 Underlying: Common Stock · 2,500 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,500 | $25.00 | $62,500.00 |
DisclosureSEC source: 0001209191-21-020468 · doc4.xml · nonDerivative · entry 2 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,899 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,500 | $1.79 | $4,475.00 |
DisclosureSEC source: 0001209191-21-020468 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-011013 · doc4.xml · derivative · entry 4 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,926 Underlying: Common Stock · 2,500 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 316 | $27.27 | $8,617.32 |
DisclosureSEC source: 0001209191-21-011013 · doc4.xml · nonDerivative · entry 3 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,899 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $27.22 to $27.315. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,184 | $26.56 | $58,007.04 |
DisclosureSEC source: 0001209191-21-011013 · doc4.xml · nonDerivative · entry 2 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,215 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.97 to $26.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,500 | $1.79 | $4,475.00 |
DisclosureSEC source: 0001209191-21-011013 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 21:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-21-003345 · doc4.xml · derivative · entry 4 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,426 Underlying: Common Stock · 2,500 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 21:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,527 | $26.74 | $40,831.98 |
DisclosureSEC source: 0001209191-21-003345 · doc4.xml · nonDerivative · entry 3 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,899 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $26.35 to $27.06. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 21:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 973 | $25.38 | $24,694.74 |
DisclosureSEC source: 0001209191-21-003345 · doc4.xml · nonDerivative · entry 2 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,426 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.08 to $25.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 21:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,500 | $1.79 | $4,475.00 |
DisclosureSEC source: 0001209191-21-003345 · doc4.xml · nonDerivative · entry 1 Sauer Paul · CIK 0001813796 · SVP Process Dev, Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,284 shares acquired under the Employee Stock Purchase Plan on November 17, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.